Loading clinical trials...
Loading clinical trials...
A Double-Blind Crossover of KB803 and Matched Placebo for the Treatment and Prevention of Corneal Abrasions in Dystrophic Epidermolysis Bullosa
Conditions
Interventions
KB803
Placebo
Locations
5
United States
Mission Dermatology Center
Rancho Santa Margarita, California, United States
Skin Research Institute
Coral Gables, Florida, United States
UMass Memorial Medical Center
Worcester, Massachusetts, United States
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
Texas Dermatology and Laser Specialists
San Antonio, Texas, United States
Start Date
June 20, 2025
Primary Completion Date
December 1, 2026
Completion Date
December 1, 2026
Last Updated
March 12, 2026
NCT05157958
NCT04213261
NCT06892639
NCT06713434
NCT05725018
NCT07011589
Lead Sponsor
Krystal Biotech, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions